Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne medication isotretinoin for the treatment of severe recalcitrant nodular acne.
“The launch of Absorica, our third commercial product, represents a major milestone for Cipher and we look forward to its successful introduction and growth in the U.S. market,” CEO Larry Andrews said in a statement.
In addition to Absorica, Cipher’s product portfolio includes a fenofibrate formulation marketed as Lipofen in the U.S., and an extended-release tramadol product marketed in the U.S. as ConZip and in Canada as Durela.